Skip to main content
. 2019 May 3;7(3):e00472. doi: 10.1002/prp2.472

Figure 2.

Figure 2

Agents in NCT clinical trials for the treatment of depression 2018 (from FDA clinicaltrials.gov (https://clinicaltrials.gov) register and EUDRA CT European trails register(https://www.clinicaltrialsregister.eu.).September, 2018). Phase III drugs—Esketamine (Spravato) for treatment resistant depression and SAGE 547 (brexanolone injection, Zulresso) for postpartum depression (PPD) both approved by FDA in 1Q2019. My thanks to Dominic Cage for help with the analysis